India Pharma Outlook Team | Tuesday, 07 October 2025
Eli Lilly announced a $1 billion investment in Telangana, aimed at expanding contract manufacturing and establishing a new advanced facility in Hyderabad. The move is expected to significantly boost the company’s global medicine supply and create substantial employment opportunities for the State’s workforce.
The company’s leadership met Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu at the Integrated Command Control Centre to discuss the investment. “Lilly’s continued expansion in Hyderabad highlights the city’s emergence as a powerhouse in global healthcare innovation. Telangana means business. Hyderabad is a global city. Our government will support and welcome all industries looking to invest here,” the Chief Minister said, recalling Hyderabad’s early pharmaceutical legacy with IDPL.
Patrik Jonsson, Executive Vice President and President, Lilly International, Eli Lilly and Company, added, “We are making significant investments to increase manufacturing and medicine supply capacity around the world to help ensure patients have access to the medicines they need.”
The Hyderabad facility, complementing the company’s global capability centre opened in August, will focus on advanced technical capabilities and monitoring of Lilly’s contract manufacturing operations in India. Recruitment for engineers, chemists, analytical scientists, quality control and assurance professionals, and management roles will begin immediately.
Also Read: India's Hospitals Face Rising Risk of U.S.-Style Fee-for-Service
Industries and IT Minister D. Sridhar Babu said, “The company’s expansion in Hyderabad is a testament to Telangana’s dynamic industrial landscape and its growing influence in advanced healthcare manufacturing. The State’s focus on technology-driven infrastructure and ease of doing business continues to attract global leaders across sectors, and the life sciences sector in particular has been on accelerated growth.”
Eli Lilly’s investment aligns with the "Make in India" agenda, marking Hyderabad as a strategic hub for global pharma innovation and sustainable growth.
